Literature DB >> 11799110

The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in Ros-induced cell transformation.

Kevin T Nguyen1, Cong S Zong, Shailaja Uttamsingh, Pallavi Sachdev, Monica Bhanot, Mai-Thao Le, Joseph L-K Chan, Lu-Hai Wang.   

Abstract

Using loss-of-function mutants of Ros and inducible epidermal growth factor receptor-Ros chimeras we investigated the role of various signaling pathways in Ros-induced cell transformation. Inhibition of the mitogen-activated protein kinase (MAPK) pathway with the MEK (MAP/extracellular signal-regulated kinase kinase) inhibitor PD98059 had little effect on the Ros-induced monolayer and anchorage-independent growth of chicken embryo fibroblasts and NIH3T3 cells even though more than 70% of the MAPK was inhibited. In contrast, inhibiting the phosphatidylinositol 3-kinase (PI3K) pathway with the drug LY294002, a dominant negative mutant of PI3K, Deltap85, or the phosphatidylinositol phosphatase PTEN (phosphatase and tensin homologue deleted in chromosome ten) resulted in a dramatic reduction of v-Ros- and epidermal growth factor receptor-Ros-promoted anchorage-independent growth of chicken embryo fibroblasts and NIH3T3 cells, respectively. Parallel and downstream components of PI3K signaling such as the Rho family GTPases (Rac, Rho, Cdc42) and the survival factor Akt were all shown to contribute to Ros-induced anchorage-independent growth, although Rac appeared to be less important for Ros-induced colony formation in NIH3T3 cells. Furthermore, the transformation-attenuated v-Ros mutants F419 and DI could be complemented by constitutively active mutants of PI3K and Akt. Finally, we found that overexpressing a constitutively active mutant of STAT3 (STAT3C) conferred a resistance to the inhibition of Ros-induced anchorage-independent growth by LY294002, suggesting a possible overlap of functions between PI3K and STAT3 signaling in mediating Ros-induced anchorage-independent growth.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799110     DOI: 10.1074/jbc.M108166200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Authors:  Lan Mo; Xiaoyong Zheng; Hong-Ying Huang; Ellen Shapiro; Herbert Lepor; Carlos Cordon-Cardo; Tung-Tien Sun; Xue-Ru Wu
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

2.  The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase.

Authors:  Matthew J Martin; Nataliya Melnyk; Michelle Pollard; Mary Bowden; Hon Leong; Thomas J Podor; Martin Gleave; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

3.  Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.

Authors:  Christina I Selinger; Bob T Li; Nick Pavlakis; Matthew Links; Anthony J Gill; Adrian Lee; Stephen Clarke; Thang N Tran; Trina Lum; Po Y Yip; Lisa Horvath; Bing Yu; Maija R J Kohonen-Corish; Sandra A O'Toole; Wendy A Cooper
Journal:  Histopathology       Date:  2016-11-15       Impact factor: 5.087

Review 4.  Activated RET and ROS: two new driver mutations in lung adenocarcinoma.

Authors:  Marc Bos; Masyar Gardizi; Hans-Ulrich Schildhaus; Reinhard Buettner; Juergen Wolf
Journal:  Transl Lung Cancer Res       Date:  2013-04

Review 5.  Molecular pathways: ROS1 fusion proteins in cancer.

Authors:  Kurtis D Davies; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

6.  Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.

Authors:  Peter W Schlosshauer; Wei Li; Kai-Ti Lin; Joseph L-K Chan; Lu-Hai Wang
Journal:  Gynecol Oncol       Date:  2009-07-02       Impact factor: 5.482

Review 7.  ROS1-dependent cancers - biology, diagnostics and therapeutics.

Authors:  Alexander Drilon; Chelsea Jenkins; Sudarshan Iyer; Adam Schoenfeld; Clare Keddy; Monika A Davare
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

Review 8.  Rho GTPases modulate malignant transformation of tumor cells.

Authors:  Jose L Orgaz; Cecilia Herraiz; Victoria Sanz-Moreno
Journal:  Small GTPases       Date:  2014-05-08

Review 9.  Treatment of Rare Mutations in Patients with Lung Cancer.

Authors:  Tarek Taha; Rasha Khoury; Ronen Brenner; Haitam Nasrallah; Irena Shofaniyeh; Samih Yousef; Abed Agbarya
Journal:  Biomedicines       Date:  2021-05-11

10.  Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway.

Authors:  Yan Li; Yi Jiang; Yicong Wan; Lin Zhang; Weiwei Tang; Jingjing Ma; Shan Wu; Wenjun Cheng
Journal:  J Biomed Res       Date:  2012-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.